fda cleared semaglutide immunoassay New Novo Nordisk initiatives support patient access to authentic, FDA- approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect fda cleared semaglutide immunoassay detection

74 Beyond the STEP programme, the SELECT trial is an ongoing eventdriven placebocontrolled CV outcomes trial of semaglutide 2.4 mg once daily in people with overweight or obesity without diabetes and with established CV disease

Zepbound, a tirzepatide-based medication, was approved by the FDA in 2023 for chronic weight management in adults with obesity

In addition to managing blood sugar, Semaglutide provides broader metabolic benefits, such as improvements in cardiometabolic risk factors

The SURPASS-2 trial put tirzepatide head-to-head with semaglutide 1.0 mg in type 2 diabetic patients tirzepatide at all three doses (5 mg, 10 mg, 15 mg) outperformed semaglutide on weight loss and A1C reduction